| Literature DB >> 27044944 |
Wim Jiskoot1, Grzegorz Kijanka1, Theodore W Randolph2, John F Carpenter3, Atanas V Koulov4, Hanns-Christian Mahler4, Marisa K Joubert5, Vibha Jawa6, Linda O Narhi7.
Abstract
The success of clinical and commercial therapeutic proteins is rapidly increasing, but their potential immunogenicity is an ongoing concern. Most of the studies that have been conducted over the past few years to examine the importance of various product-related attributes (in particular several types of aggregates and particles) and treatment regimen (such as dose, dosing schedule, and route of administration) in the development of unwanted immune responses have utilized one of a variety of mouse models. In this review, we discuss the utility and drawbacks of different mouse models that have been used for this purpose. Moreover, we summarize the lessons these models have taught us and some of the challenges they present. Finally, we provide recommendations for future research utilizing mouse models to improve our understanding of critical factors that may contribute to protein immunogenicity.Entities:
Keywords: immunogenicity; in vivo models; protein aggregation
Mesh:
Substances:
Year: 2016 PMID: 27044944 PMCID: PMC4846475 DOI: 10.1016/j.xphs.2016.02.031
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534